Patients With Mouse Tyrp2 DNA: A Phase I Trial to Assess Safety and Immune Response

PHASE1CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

July 31, 2006

Primary Completion Date

March 31, 2011

Study Completion Date

March 31, 2011

Conditions
Melanoma
Interventions
BIOLOGICAL

injection of mouse TYRP2 DNA

Cohorts of three patients will receive injections with mouse TYRP2 DNA delivered intramuscularly at four different dose levels (500, 2000, 4000 or 8000 μg) every three weeks for six injections.

Trial Locations (1)

10065

Memorial Sloan-Kettering Cancer Center, New York

All Listed Sponsors
lead

Memorial Sloan Kettering Cancer Center

OTHER

NCT00680589 - Patients With Mouse Tyrp2 DNA: A Phase I Trial to Assess Safety and Immune Response | Biotech Hunter | Biotech Hunter